论文部分内容阅读
目的:观察升血丸对恶性肿瘤患者化疗后血液指标的影响。方法:86例恶性肿瘤患者化疗后白细胞下降者属脾肾两虚证型者分为两组,每组43例,治疗组口服升血丸配合皮下注射G-CSF每日200μg,对照组皮下注射G-CSF每日200μg,并观察两组患者治疗前后血液指标变化情况。结果:治疗5天对照组白细胞上升至超出正常范围,且高于治疗组,差异有统计学意义(P<0.01),治疗组血小板水平较对照组升高,差异有统计学意义(P<0.05);治疗10天对照组白细胞下降,治疗组白细胞仍在正常范围水平,差异有统计学意义(P<0.05),治疗组血小板水平较对照组高,差异有统计学意义。结论:升血丸用于晚期恶性肿瘤患者化疗后骨髓移植的辅助治疗,有辅助粒细胞集落刺激因子升高白细胞的作用,能使白细胞稳步上升并长期稳定在正常范围内,并且对血小板有迅速提升作用,用于化疗后白细胞下降及轻度血小板减少有良好的治疗作用值得临床推广应用。
Objective: To observe the effect of Shengxue Pill on the blood parameters after chemotherapy in malignant tumor patients. Methods: Eighty-six patients with malignant neoplasm who had leukopenia after chemotherapy were divided into two groups (43 cases in each group). The treatment group received 200 μg of G-CSF orally, and the control group received subcutaneous injection G-CSF daily 200μg, and observed changes in blood parameters before and after treatment in two groups of patients. Results: The white blood cells in the control group increased beyond the normal range on the 5th day after treatment, and the difference was statistically significant (P <0.01). The platelet level in the treatment group was significantly higher than that in the control group (P <0.05 ); The white blood cells in the control group decreased 10 days after treatment, and the leukocytes in the treatment group were still in the normal range, the difference was statistically significant (P <0.05). The platelet level in the treatment group was higher than that in the control group. The difference was statistically significant. Conclusion: Sheng Xue Wan is an adjuvant therapy for patients with advanced malignant neoplasm after bone marrow transplantation after chemotherapy. It has the effect of promoting granulocyte colony-stimulating factor to increase white blood cells, stabilizing white blood cells and long-term stable in the normal range, and has rapid response to platelets Enhance the role of chemotherapy for leukopenia and mild thrombocytopenia have a good therapeutic effect worthy of clinical application.